ESMO Sarcoma and Rare Cancers 2023 | MDM2 as a target for milademetan in liposarcoma treatment

Chiara Fabbroni, MD, Fondazione IRCCS, Milan, Italy, discusses the rationale behind targeting murine double minute 2 homolog (MDM2) in patients with liposarcoma. Milademetan is an inhibitor of the MDM2 and p53 interaction, whereby MDM2 prevents transcription of p53. The importance of p53 in cancers and the fact that MDM2 is often amplified in liposarcoma tumors, makes MDM2 a suitable target. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.